Filing Details
- Accession Number:
- 0001209191-20-008878
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-12 17:19:08
- Reporting Period:
- 2020-02-10
- Accepted Time:
- 2020-02-12 17:19:08
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1242825 | M Jeffrey Leiden | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Ceo & President | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-02-10 | 36,755 | $240.95 | 180,063 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2020-02-11 | 2,800 | $243.37 | 177,263 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-11 | 4,124 | $244.56 | 173,139 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-11 | 14,024 | $245.37 | 159,115 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-11 | 14,433 | $246.27 | 144,682 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-11 | 7,533 | $247.49 | 137,149 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-11 | 4,609 | $248.45 | 132,540 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 440 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1.
- Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $243.37 (range $242.88 to $243.84).
- Open market sales reported on this line occurred at a weighted average price of $244.56 (range $243.91 to $244.90).
- Open market sales reported on this line occurred at a weighted average price of $245.37 (range $244.91 to $245.90).
- Open market sales reported on this line occurred at a weighted average price of $246.27 (range $245.91 to $246.87).
- Open market sales reported on this line occurred at a weighted average price of $247.49 (range $246.92 to $247.88).
- Open market sales reported on this line occurred at a weighted average price of $248.45 (range $248.02 to $248.97).
Billionaire Hedge Funds
